Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral kinetics and mathematical models.

A S Perelson1

  • 1Theoretical Biology and Biophysics, Los Alamos National Laboratory, New Mexico 87544, USA.

The American Journal of Medicine
|February 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

Journal of viral hepatitis·2016
Same author

Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

A perspective on modelling hepatitis C virus infection.

Journal of viral hepatitis·2010
Same author

Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.

Journal of viral hepatitis·2008
Same author

Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b.

Journal of viral hepatitis·2008
Same author

Th1/Th2 differentiation and cross-regulation.

Bulletin of mathematical biology·2007
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Mathematical models reveal how interferon dosage impacts hepatitis C virus (HCV) production. Higher interferon doses significantly block more HCV, suggesting a key role in viral dynamics and treatment strategies.

Area of Science:

  • Virology
  • Mathematical Modeling
  • Pharmacology

Background:

  • Viral dynamics studies, particularly for human immunodeficiency virus (HIV), can be adapted to understand hepatitis C virus (HCV) infection.
  • Interferon therapy is a treatment for HCV, but its precise mechanisms and dose-dependent effects require further elucidation.

Purpose of the Study:

  • To apply mathematical modeling to analyze HCV dynamics in patients treated with varying interferon dosages.
  • To investigate the mechanism of action of interferon in reducing HCV levels.
  • To determine the consequences of different interferon dosages on HCV production and clearance.

Main Methods:

  • Mathematical modeling was used to analyze in vivo HCV dynamics.
  • Patients received daily interferon doses of 5, 10, or 15 mIU for 14 days, followed by maintenance therapy.

Related Experiment Videos

  • HCV-RNA levels in serum were monitored throughout the treatment period.

    • Main Results:

    • HCV-RNA levels dropped rapidly within the first 1-2 days of interferon therapy.
    • Mathematical models suggest interferon primarily blocks HCV production or release from infected cells.
    • A daily dose of 5 mIU blocked ~80% of HCV production, while 10 and 15 mIU doses blocked ~95%.

    Conclusions:

    • Interferon therapy effectively reduces HCV production in a dose-dependent manner.
    • Mathematical modeling provides valuable insights into viral kinetics and treatment efficacy.
    • Further research is needed to fully understand the second-phase decline of HCV and its correlation with immune responses and eradication.